Clascoterone (Winlevi) Update for Canada
Treatment 11/10/2022
clascoterone Winlevi finasteride androgenic alopecia scarring alopecia Lichen Planopilaris FDA Health Canada Propecia AGA
Clascoterone cream was submitted for review to Health Canada in August 2022, with hopes of approval within 3-6 months. It may potentially enhance finasteride's effects for hair loss treatment.
View this post in the Community →
Similar Community Posts Join
5 / 95 resultscommunity Clascoterone vs fluridil, and using them with minoxidil
The user is considering minoxidil, clascoterone, and fluridil for hair loss, avoiding finasteride and RU58841. They are also contemplating a hair transplant and exploring the resilience of transplanted hair without finasteride.
community Clascoterone study going on right now
A user is participating in a phase 3 trial for Clascoterone, a topical acne medication that may stimulate hair growth, and will share results after 6 months. They will have a section of their hair shaved and marked with a tattoo for the study.
community Clascoterone (Winlevi) now approved in Canada
The conversation is about the approval of Clascoterone (Winlevi) in Canada for hair loss treatment. One user expressed skepticism about its effectiveness due to low concentration.
community Move Over Finasteride and Minoxidil....Clascoterone is the new Bitcoin of Hair Loss Products
Clascoterone lotion, being tested in Germany, is as effective as Minoxidil and Finasteride for hair loss but without serious side effects. About 400 men participated in the trials.
community CASSIOPEA ANNOUNCES VERY POSITIVE PHASE II TWELVE MONTHS RESULTS FOR BREEZULA® (CLASCOTERONE) IN TREATING ANDROGENETIC ALOPECIA
Clascoterone (Breezula) showed positive results for treating hair loss without affecting cortisol levels. Opinions vary, with some users optimistic about its potential and others critical of its effectiveness compared to existing treatments like finasteride.
Related Research
6 / 56 results
research Androgens and Acne: Perspectives on Clascoterone, the First Topical Androgen Receptor Antagonist
Clascoterone is a new, effective, and safe acne treatment without systemic side effects.
research Clascoterone as a Novel Treatment for Androgenetic Alopecia
Clascoterone may be a promising treatment for hair loss.
research Biological Profile of Cortexolone 17a-Propionate (CB-03-01), a New Topical and Peripherally Selective Androgen Antagonist
CB-03-01 is a promising skin cream for treating hormone-related skin problems without causing harmful body-wide effects.
research Cortexolone 17α-Propionate (Clascoterone) Is an Androgen Receptor Antagonist in Dermal Papilla Cells In Vitro
Clascoterone may be an effective topical treatment for hair loss.
research A Summary of In Vitro, Phase I, and Phase II Studies Evaluating the Mechanism of Action, Safety, and Efficacy of Clascoterone (Cortexolone 17a Propionate, CB-03-01) in Androgenetic Alopecia
Clascoterone safely promotes hair growth similar to minoxidil.
research A Phase 1 Study to Investigate the Effects of Cortexolone 17α-Propionate, Also Known as Clascoterone, on the QT Interval Using the Meal Effect to Demonstrate ECG Assay Sensitivity
Clascoterone is safe for the heart, even at high doses.